Physician profile
Carlos Vidal
NPI 1891783932
$15,652.79
in general payments reported to CMS, 2019-2025
61 companies · $4,226 in 2025
The $4,226 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,610 · 2021: $488 · 2022: $1,528 · 2023: $2,570 · 2024: $5,231 · 2025: $4,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $517 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,009.72 |
| Education | $516.88 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,113.21 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Celgene Corporation | $1,464.57 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $1,272.40 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Pfizer INC. | $1,118.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,116.69 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $727.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $611.37 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $571.73 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Verity Pharmaceuticals INC. | $549.66 | 2023-2024 | Trelstar |
| Daiichi Sankyo INC. | $516.75 | 2022-2025 | Enhertu, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $428.23 | 2019-2025 | |
| Lilly USA, LLC | $395.48 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $392.53 | 2023-2025 | Ninlaro, Iclusig, Alunbrig |
| Amgen INC. | $297.04 | 2021-2023 | Vectibix, Lumakras |
| Astellas Pharma US INC | $246.29 | 2019-2025 | Xospata, Vyloy, Padcev |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.81 | 2019-2025 | Lupron Depot |
| Seagen INC. | $237.93 | 2019-2024 | Tukysa, Padcev |
| Regeneron Healthcare Solutions, INC. | $234.77 | 2024-2025 | Libtayo, Lynozyfic |
| Beigene USA, INC. | $227.61 | 2022-2024 | Brukinsa |
| Array Biopharma INC | $226.25 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Genzyme Corporation | $192.74 | 2019-2025 | |
| Emd Serono, INC. | $162.37 | 2022-2025 | Bavencio |
| Eisai INC. | $149.25 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $123.61 | 2019-2025 | Onivyde |
| Glaxosmithkline, LLC. | $121.97 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Kite Pharma, INC. | $116.66 | 2023 | Yescarta |
| Sobi, INC | $114.98 | 2023-2025 | |
| Mirati Therapeutics, INC. | $108.62 | 2023-2024 | Krazati |
| Sun Pharmaceutical Industries INC. | $108.34 | 2019-2024 | |
| Exelixis INC. | $103.87 | 2019-2025 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $101.10 | 2023-2025 | Monoferric |
| Genentech USA, INC. | $96.77 | 2023-2025 | Polivy, Tecentriq |
| Tempus Ai, INC | $91.61 | 2024-2025 | Xt Cdx |
| Taiho Oncology, INC. | $89.38 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $88.56 | 2022-2025 | Myrisk |
| Gilead Sciences, INC. | $81.49 | 2022-2025 | Trodelvy |
| Amneal Pharmaceuticals LLC | $77.14 | 2023-2025 | Avastin, Neulasta, Neupogen |
| Caris Mpi, INC. | $62.34 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $54.82 | 2025 | |
| Rigel Pharmaceuticals, INC. | $53.30 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Stemline Therapeutics INC. | $52.62 | 2025 | Orserdu |
| Iovance Biotherapeutics, INC. | $47.46 | 2025 | Amtagvi |
| Dendreon Pharmaceuticals LLC | $44.96 | 2025 | Provenge |
| Cti Biopharma Corp. | $35.00 | 2022-2023 | Vonjo |
| Pharmaand Gmbh | $28.97 | 2025 | Rubraca |
| Servier Pharmaceuticals LLC | $28.38 | 2025 | |
| Tesaro, INC. | $27.71 | 2019 | |
| Kyowa Kirin, INC. | $27.42 | 2025 | |
| Blue Earth Diagnostics | $26.31 | 2021 | |
| Genmab U.S., INC. | $25.93 | 2025 | Epkinly |
| Syndax Pharmaceuticals, INC. | $25.25 | 2025 | |
| Beone Medicines USA, INC. | $23.62 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $22.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.44 | 2019 | |
| Adaptive Biotechnologies Corporation | $20.58 | 2025 | Clonoseq |
| Springworks Therapeutics, INC. | $20.11 | 2024 | Ogsiveo |
| Adc Therapeutics America, INC. | $17.80 | 2022 | |
| Puma Biotechnology, INC. | $17.25 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.58 | 2025 | |
| Deciphera Pharmaceuticals INC. | $16.43 | 2021 | |
| Tolmar, INC. | $16.13 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Vidal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.